Caplin Point Laboratories’ arm gets USFDA’s nod for Ropivacaine Hydrochloride injection

13 Apr 2020 Evaluate
Caplin Point Laboratories’ wholly owned subsidiary -- Caplin Steriles has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ropivacaine Hydrochloride injection USP, 0.2 % in 40 mg/20 mL (2 mg/mL), 0.5 % in 100 mg/20 mL (5 mg/mL), 0.5 % in 150 mg/30 mL (5 mg/mL) and 1 % in 200 mg/20 mL (10 mg/mL) Single-dose vial presentations, a generic therapeutic equivalent version of (RLD), NAROPIN Injection, of Fresenius Kabi USA LLC.

According to IQVIATM (IMS Health), Ropivacaine Hydrochloride injection USP had US sales data of approximately $34 million for the 12-month period ending Dec 2019. The company, has developed and filed 16 ANDAs on its own and with partners, with 8 approvals so far. Ropivacaine Hydrochloride is a long acting local anesthetic drug used for surgery or acute pain management.

Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.

Caplin Point Lab Share Price

1918.15 -50.20 (-2.55%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×